Amendments to the Claims

1-6. (canceled)

7. (currently amended) A method of treatment, comprising:

a) providing:

i) a mammal having symptoms of sepsis,

ii) a therapeutic preparation lacking a cytokine receptor antagonist, comprising anti-TNF-α and anti-IL-6 antibodies; and

iii) administering said preparation to said mammal wherein said symptoms are reduced.

8. (previously presented) The method of Claim 7, wherein said therapeutic preparation further comprises anti-IFN antibodies.

9. (previously presented) The method of Claim 7, wherein said mammal is a human.

10. (previously presented) The method of Claim 7, wherein said administering is performed intravenously.

11. (previously presented) The method of Claim 7, wherein said administering is performed orally.

12. (previously presented) The method of Claim 7, wherein said administering is performed parenterally.

13-14. (canceled)

15. (previously presented) The method of Claim 7, wherein said antibodies are polyclonal antibodies.

16. (previously presented) The method of Claim 15, wherein said polyclonal antibodies are avian antibodies.

17. (previously presented) The method of Claim 16, wherein said avian antibodies are chicken antibodies.

18. (previously presented) The method of Claim 17, wherein said chicken antibodies are derived from chicken eggs.

19-33. (canceled)

34. (previously presented) A method of treatment, comprising:

a) providing:

i) a mammal having symptoms of sepsis,

ii) a therapeutic preparation, consisting of anti-TNF-α and anti-IL-6 antibodies, and one or more inactive ingredients; and

iii) administering said preparation to said mammal wherein said symptoms are reduced.

35. (previously presented) The method of Claim 34, wherein said inactive ingredient is bovine serum albumin.

36. (previously presented) The method of Claim 34, wherein said mammal is a human.

37. (previously presented) The method of Claim 34, wherein said administering is performed intravenously.

38. (previously presented) The method of Claim 34, wherein said administering is performed orally.

39. (previously presented) The method of Claim 34, wherein said administering is performed parenterally.

40. (previously presented) The method of Claim 34, wherein said antibodies are polyclonal antibodies.

41. (previously presented) The method of Claim 40, wherein said polyclonal antibodies are avian antibodies.

42. (currently amended) A method of treatment, comprising:

a) providing:

i) a mammal having symptoms of sepsis,

ii) a therapeutic preparation lacking a cytokine receptor antagonist, comprising polyclonal anti-TNF-α and polyclonal anti-IL-6 antibodies; and

iii) administering said preparation to said mammal wherein said symptoms are reduced.

43. (previously presented) The method of Claim 42, wherein said therapeutic preparation further comprises anti-IFN antibodies.

44. (previously presented) The method of Claim 42, wherein said mammal is a human.

45. (previously presented) The method of Claim 42, wherein said administering is performed intravenously.

46. (previously presented) The method of Claim 42, wherein said administering is performed orally.

47. (previously presented) The method of Claim 42, wherein said administering is performed parenterally.

48. (previously presented) The method of Claim 42, wherein said polyclonal antibodies are avian antibodies.

49. (New) A method of treatment, comprising:

a) providing:

i) a mammal having symptoms of sepsis,

ii) a therapeutic preparation, comprising anti-TNF-alpha, anti-IL-6, and anti-IFN antibodies; and

b) administering said preparation to said mammal wherein said symptoms are reduced.

50. (New) The method of Claim 49, wherein said antibodies are polyclonal.

51. (New) A therapeutic composition for use with a mammal having symptoms of sepsis, said therapeutic composition comprising anti-TNF-alpha, anti-IL-6, and anti-IFN antibodies.